Heptares Therapeutics Ltd
Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.
Heptares Therapeutics Ltd has already four-year collaboration with AstraZeneca (2011), where they focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Also, an approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.
Moreover, $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.
| Type: | NORMAL |
| Address: | BioPark, Broadwater Rd, Welwyn Garden City, Hertfordshire AL7 3AX |
| Website: | http://www.mvmlifescience.com |
| Phone: | +44 (0) 1707 358 629 |
| Fax: | +44 (0) 7968947268 |
| Email: | Malcolm.weir@heptares.com |